The Soul of Biotech
The blog and website of Jonathan Sheffi, Biotechnology Catalyst
biotech, jonathan, sheffi, medicine, cancer, really, dollars, category, health, recent, create, pathway, waxman, president, obama, generic, later, industry, biologic, drugs, anemia, right, biosimilars, truly, healthcare, savings, challenges, approval, traditional, small, molecule, therapies, think, probably, tylenol, attention, policymakers, media, different, manufacturing, therapeutic, actually, enbrel, several, pharmaceutical, designed, patient, currently, companies, develop, exclusivity, market, order, cells, codes, process, company, therapy, eprex, european, version, change, blood, adverse, protein, expensive, treatment, worth, important, programs, manufacturer, payors, public, insurance, insurers, physician, given, bioequivalence, patent, research, clinical, trials, marketing, original, allow, reference, listed, approved, interchangeability, product, response, current, identical, technology, competition, pricing, brand, safety, business, expenses, recently, report, policy, eshoo, structure, years, billion, model, option, costs, makes, first, harvard, school, information, personal, transparency, meeting, posterous, comment, video, online, personalized, outcomes, genetic, employers, based, mentioned, conference, notes, january, pharma, panel, fipco, cairns, smith, goulet, pointed, emphasized, value, explained, genome, diagnostics, intuitive, disruptive, adoption, networks, gautham, facebook, promotion, contest, really save, save billions, pathway generic, generic biologics, generic biologic, generic versions, biologic manufacturers, data exclusivity, molecule drugs, biologic therapies, manufacturing process, generic drug, listed drug, years data, harvard business, business school, personalized medicine, treatment response, genetic information, healthcare conference, comments notes, notes harvard, school healthcare, conference part, part january, really save billions, save billions dollars, pathway generic biologics, small molecule drugs, reference listed drug, years data exclusivity, harvard business school, comments notes harvard, notes harvard business, business school healthcare, school healthcare conference, healthcare conference part, conference part january
